Pharmaceutical manufacturers of Finasteride

Dr. Reddy’s Laboratories Ltd. functions as an integrated pharmaceutical firm, dedicated to supplying cost-effective and innovative medications to promote healthier lifestyles. With a focus on Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products, Dr. Reddy’s delivers a range of products and services such as APIs, customized pharmaceutical services, generics, biosimilars, and distinct formulations. The primary therapeutic areas of concentration encompass gastro-intestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s has a presence in various global markets, with significant engagements in the USA, Europe, India, Russia, and other CIS nations.

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.

We are one of world’s leading producers of key Active Pharmaceutical Ingredients (APIs) and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector. We endeavour to serve patients by moulding science and technology into therapies to improve health outcomes and people’s lives.

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA. The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible.

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.

Fisvi is a distinguished Italian company with a proud heritage in the manufacturing and innovation sectors. Specializing in advanced materials and cutting-edge solutions, Fisvi offers a wide range of products tailored to meet the demands of various industries, including construction, automotive, and industrial applications. Their product lineup includes high-quality insulation materials, adhesives, sealants, and other specialized components designed to enhance performance and durability.

Swati Spentose (SSPL) is a technology-driven manufacturing company specializing in the production and supply of both APIs & FDFs. Swati Spentose Pvt. Ltd. (SSPL) Unit 1 has been inspected by USFDA, certified by EU-GMP, approved by COFEPRIS in Mexico & MFDS in Korea, and WHO-GMP certified (www.spentose.com). They offer products such as Polysaccharide Block-Pentosan Polysulfate Sodium (PPS), Multipurpose Block-Lidocaine Base/HCl, Meloxicam, Melatonin, Granisetron Base/HCl, Prilocaine Base/HCL, Glycopyrrolate, Tamsulosin, Silodosin, Mirabegron. SSPL Unit-2 details are not provided.

Founded as Xianju Pharmacy Plant in 1972, Xianju Pharmaceutical Co., Ltd. (stock code: 002332) practices the corporate philosophy of “ your health and happiness, my sincerity and service” and focuses on steroid hormones with the vision of “ Becoming the one of the Top 10 steroid hormone suppliers in the world and a business well-received among customers and employees.” It has a total capital stock of 989.204866 million yuan and more than 3600 employees. As a key high-tech enterprise of the National Torch Plan, the company ranked 67th among the top 100 in the Chinese pharmaceutical industry in 2020 with a provincial steroid medicine engineering technology research center in Zhejiang Province and a national post-doctoral center. As the only company holding fast to the business pattern integrating bulk pharmaceutical chemicals and preparations, the company specializes in the research, production and sale of bulk pharmaceutical chemicals and steroid preparations. In its product development, the company sticks to the four major fields of health care (gynecology, anesthesiology, respiratory medicine, and dermatology) to build mixes of products and services. The company has established long-term partnership with more than 20 domestic prestigious research institutes and universities including the Shanghai institute of Organic Chemistry, Chinese Academy of Sciences, Zhejiang University and China Pharmaceutical University to bring in senior researchers and gradually align with the new drug development in the world. The company has formed a technical framework that originates from overseas high-end research institutions, assimilates through the research institutions in Hangzhou and Xianju and Implements them with the base in Xianju. Under the company, there are 20 wholly-owned and holding subsidiaries such as time Xianju Pharmaceutical Co., Ltd. The company has three core manufacturing platforms, which are Xianju Yangfu bulk pharmaceutical chemicals production zone, Xianju Yangfu preparation production zone and Linhai Yangfu productions zone at home and two standard bulk pharmaceutical chemicals plants under the name of NewChem, its subsidiary in Italy. Xianju Pharma advocates the culture celebrating authenticity, win-win results and innovation and core values of honesty, hard work, openness, studiousness, responsibility and mutual benefit. Upholding the strategic objective of achieving win-win results with customers, enterprises, employees and communities, the company promotes the values that individuals’ value is reflected when they benefit their communities and companies. In its future development, the company will continue optimizing its business management, developing high-tech products and leverage on its large business size to achieve high-quality development and make contributions to the health care of mankind.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Shree Venkatesh International Limited has established itself as a rapidly growing and distinguished Indian company dedicated to the production, promotion, and export of Hormonal products. Our state-of-the-art facility is equipped with advanced technologies specifically designed for a wide range of Gynecological, IVFs, and Contraceptives Hormonal products. At Shree Venkatesh International Limited, we tirelessly strive to develop highly efficient and safe hormonal products and make them accessible at the most competitive prices globally. Our portfolio includes Injectables, lyophilized powder, and hormonal Oral tablets, contributing to the enhancement of reproductive health on a global scale. Our WHO-GMP (India) plant has been inspected and approved by regulatory bodies in Yemen (SBDMA), Kenya (PPB), Nigeria (NAFDAC), Cambodia, and the Philippines. We have plans to extend our product reach to countries in the CIS, African, Southern Asian, Southern American, PIC/s, and MENA regions. For further information, please visit www.shreevenkatesh.com. Shree Venkatesh International Limited is an ISO9001:2008 Certified company registered under the Registrar of Companies Act, specializing in the export of Generic Medicines, Pharmaceutical formulations, and Bulk drugs from India. The company is based in Gujarat, which is renowned as the Manufacturing Hub for Pharmaceutical formulations in India.

Sterling, established in 1976, is a specialized firm dedicated solely to the development and production of steroidal APIs. Our expertise spans from large-scale, highly automated manufacturing to smaller-scale specialized production requiring more hands-on attention. Our manufacturing facilities are equipped with cutting-edge control systems and are highly contained in their environment. Sterling API facilities have a strong compliance track record and have undergone thorough FDA and AIFA (Italian Health Authority) audits.

JW Holdings is advancing towards becoming a global healthcare group. As a holding company, we are directing all our efforts to ensure the steady growth of our business entities, which include JW Pharmaceutical, JW Shinyak, JW Life Science, and JW Medical. Moreover, JW Holdings, a business holding firm, is directly managing the international business for raw materials, finished pharmaceuticals, medical devices, and more.

Ryoto Fine Co., Ltd. engages in exploration and development, production, production and distribution across a diverse spectrum of sectors such as pharmaceutical ingredients, medicinal preparations, quasi-medicines, beauty products, industrial chemicals, food additives, assorted cleansers, and personal care products. As a versatile chemical provider handling quantities from milligrams to tons, we are dedicated to delivering valuable goods of enhanced caliber. Our aspiration is to contribute to the well-being of numerous individuals within the chemistry domain.